
Corona Remedies Q3 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- CORONA Remedies aims for 15% compound annual growth rate (CAGR) in revenue over the next 3 to 4 years.
- The target for profit after tax (PAT) or earnings per share (EPS) growth is around 20% year-on-year for the next 3 to 4 years.
- Revenue growth is generally steady with minor seasonal variations; Q3 sees slightly less growth due to festive season.
- The company plans to expand its sales force by 5-7% annually, supporting growth and new therapy launches.
- Expansion into new therapies like infertility, spine, rheumatoid, CNS, dermatology, and gastrointestinal is expected to drive additional growth.
- International business is in early stages but aims to contribute with hormonal products post plant commissioning, targeting higher single-digit contribution in a couple of years.
See what Corona Remedies management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript does not mention any current or planned fundraising through equity.
- There is no explicit discussion about raising debt in the call.
- Focus appears to be on organic growth and limited acquisitions (small acquisition from Bayer-Zydus done recently around INR 7.5-8 crores).
- Plans include expanding manufacturing capacity, launching new therapies, and increasing marketing force funded through internal accruals.
- No direct indication of external fundraising through either debt or equity in the immediate or near future.
See what Corona Remedies management said on order book — free account, 30 seconds.
Capex plans
Yes- CORONA Remedies is investing in a new hormonal manufacturing plant in Ahmedabad, which has received the state Schedule M license and is expected to commence commercial production by Q2-end or early Q3 of FY '27.
- The company aims to obtain WHO and EU GMP certifications for this plant by the end of FY '27 to ramp up its international hormonal products business.
- There is a significant solar power investment: an existing 1.3 MW solar plant at Bhayla and a planned 4.25 MW solar park covering 11.9 acres, aimed at reducing electricity costs and supporting ESG initiatives.
- CORONA is actively evaluating inorganic growth opportunities via M&A and in-licensing but remains selective, focusing on strategic fit and brand alignment rather than solely company origin.
- The focus is on expanding marketing and field force by 5-7% annually to support growth and new therapy launches, indirectly requiring investment in human capital.
Track Corona Remedies — get its next earnings analysis in your feed
How does Corona Remedies rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Corona Remedies rank in Pharmaceuticals & Biotechnology?
Compare Corona Remedies against every Pharmaceuticals & Biotechnology company (Q3 FY26) on revenue, margins and earnings-call signals.
Continue your research
What Corona Remedies's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem